in situ carcinoma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- in situ carcinoma
- Therapeutic area
- Oncology
- in situ carcinoma
- CIS
- carcinoma in situ
- carcinoma, in situ, malignant
- epithelial tumor, in situ, malignant
- intraepithelial carcinoma
- non-invasive carcinoma
- stage 0 disease
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0004647
- Parent condition
- MONDO:0004993
Related records
Broader conditions (11)
- Cancer
- Cancer or benign tumor
- Carcinoma
- Disease
- Disease by etiologic mechanism
- Epithelial neoplasm
- High grade malignant neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Precancerous condition
Narrower conditions (52)
- Adenocarcinoma in situ
- Anal canal carcinoma in situ
- Atypical lobular breast hyperplasia
- Bile duct carcinoma in situ
- Bladder carcinoma in situ
- Bowen disease of the skin
- Breast apocrine carcinoma in situ
- Breast carcinoma in situ
- Bronchus carcinoma in situ
- Carcinoma in situ of appendix
- Carcinoma in situ of cecum
- Carcinoma in situ of epiglottis
- Carcinoma in situ of extrahepatic bile duct
- Carcinoma in situ of fundus of stomach
- Carcinoma in situ of gastric body
- Carcinoma in situ of gastric cardia
- Carcinoma in situ of hypopharynx
- Carcinoma in situ of nasopharynx
- Carcinoma in situ of oropharynx
- Carcinoma in situ of renal pelvis
Trials (81)
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
- A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
- Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer
- Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases
- Cervical And Self-Sample In Screening Study
- Chromoscopic Guided Endomicroscpy to Diagnose Colitis Associated Dysplasia
- Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
- Colposcopy in Detection of Oral Epithelial Dysplasia
- Comparison of pCLE and EB in Gastric Lesion Diagnosis
- Difference of Gastric Microbiota in the Process of Correa's Model.
- Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
- Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers
- Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing
- Effectiveness of Cervical Screening in Unvaccinated, Herd Effect Protected Women (HPV400)
Drugs in development (4)
- Aminolevulinic acid hydrochloride Phase 1
- Cholecalciferol Phase 1
- Mitomycin Phase 3
- Valrubicin Phase 3